Compare PRG & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | VERA |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | PRG | VERA |
|---|---|---|
| Price | $29.76 | $46.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $37.50 | ★ $76.60 |
| AVG Volume (30 Days) | 605.8K | ★ 1.5M |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $2,507,179,000.00 | N/A |
| Revenue This Year | $1.24 | N/A |
| Revenue Next Year | $7.02 | N/A |
| P/E Ratio | $7.42 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $23.50 | $18.53 |
| 52 Week High | $44.43 | $56.05 |
| Indicator | PRG | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 53.97 |
| Support Level | $30.10 | $47.22 |
| Resistance Level | $30.76 | $56.05 |
| Average True Range (ATR) | 0.73 | 2.35 |
| MACD | -0.11 | -1.00 |
| Stochastic Oscillator | 33.56 | 9.63 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.